Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Trial Details

NCT ID

NCT07253896

Phase

PHASE2

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

• AK104 and cetuximab or bevacizumab and FOLFIRI

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142
• Hangzhou, China|30.29365,120.16142

Key Eligibility Criteria

• 1\. Voluntarily sign a written ICF. 2. Age at enrollment: ≥ 18 years old, ≤ 75 years old, both male and female. 3. The Eastern Cancer Collaborative…
• 4\. The expected survival period is ≥ 3 months. 5. Metastatic colorectal adenocarcinoma confirmed by histology or cytology. 6. Microsatellite insta…
• 8\. Previously only received first-line systemic anti-tumor therapy based on oxaliplatin (FOLFOX or CAPOX), and other systemic anti-tumor treatment…
• According to RECIST v1.1, subjects must have at least one measurable lesion. For subjects who have previously received radiotherapy, if there are n…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.